Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis
- PMID: 19937358
- DOI: 10.1007/s00774-009-0138-7
Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis
Abstract
Dual-energy X-ray absorptiometry-based hip structural analysis was performed to evaluate the effect of a bisphosphonate, minodronic acid hydrate, on the geometry of the proximal femur in Japanese patients with osteoporosis. The subjects were 103 postmenopausal patients (average age 63.9 +/- 6.4 years) with primary osteoporosis. Minodronic acid hydrate was administered orally at a dose of 1 mg/day for 12 months. Significant early responses at 3-6 months after the start of administration were observed in all three regions of the proximal femur (narrow neck, intertrochanter, and shaft) in terms of bone density, geometry, and bone strength indices. The outcomes of therapy included a reduction of the internal diameter of the cortical bone (-0.1, -0.6, and -0.2% in the neck, intertrochanter, and shaft, respectively, at 12 months; not significant) and a significant increase in cortical thickness (3.1, 3.7, and 2.0% in the respective regions at 12 months). Furthermore, minodronic acid hydrate induced a significant enlargement of the cross-sectional bone area, which is related to compressive strength; a significant increase in cross-sectional moment of inertia and section modulus (SM 4.9, 5.8, and 2.9% in the neck, intertrochanter, and shaft, respectively, at 12 months; P < 0.001), which are related to the bending strength; and a significant reduction in buckling ratio (BR -3.0% (P < 0.001), -4.2% (P < 0.001), and -1.4% (P < 0.05) in the respective regions at 12 months), which reflects improved cortical stability. These findings show that minodronic acid hydrate reduces age-related endocortical bone resorption, leading to increased cortical thickness and sustained or enhanced bone strength.
Similar articles
-
A review of minodronic acid hydrate for the treatment of osteoporosis.Clin Interv Aging. 2013;8:185-9. doi: 10.2147/CIA.S23927. Epub 2013 Feb 15. Clin Interv Aging. 2013. PMID: 23440003 Free PMC article. Review.
-
Efficacy and safety of minodronic acid hydrate in patients with steroid-induced osteoporosis.Int J Rheum Dis. 2018 Apr;21(4):813-820. doi: 10.1111/1756-185X.12844. Epub 2016 Mar 1. Int J Rheum Dis. 2018. PMID: 26929019 Clinical Trial.
-
The effects of bazedoxifene on bone structural strength evaluated by hip structure analysis.Bone. 2015 Aug;77:115-9. doi: 10.1016/j.bone.2015.04.027. Epub 2015 Apr 23. Bone. 2015. PMID: 25917574 Clinical Trial.
-
Combined use of ibandronate and eldecalcitol in postmenopausal Japanese women with osteoporosis.J Orthop Surg (Hong Kong). 2016 Dec;24(3):362-366. doi: 10.1177/1602400318. J Orthop Surg (Hong Kong). 2016. PMID: 28031507
-
[Minodronic acid hydrate as a new therapeutic agent for osteoporosis].Clin Calcium. 2005 Jan;15(1):9-14. Clin Calcium. 2005. PMID: 15632466 Review. Japanese.
Cited by
-
Three-Dimensional Bowing Measurement of Distal Femur at Actual Size and Clinical Implications of Total Knee Arthroplasty.Medicina (Kaunas). 2024 Jun 15;60(6):986. doi: 10.3390/medicina60060986. Medicina (Kaunas). 2024. PMID: 38929603 Free PMC article.
-
The effect of zoledronic acid on hip geometry in renal transplant recipients: a double-blind placebo-controlled randomized study.BMC Nephrol. 2023 Nov 8;24(1):331. doi: 10.1186/s12882-023-03376-y. BMC Nephrol. 2023. PMID: 37940839 Free PMC article. Clinical Trial.
-
Minodronate for the treatment of osteoporosis.Ther Clin Risk Manag. 2018 Apr 17;14:729-739. doi: 10.2147/TCRM.S149236. eCollection 2018. Ther Clin Risk Manag. 2018. PMID: 29713181 Free PMC article. Review.
-
A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients.J Bone Miner Metab. 2013 Mar;31(2):153-60. doi: 10.1007/s00774-012-0393-x. Epub 2012 Oct 19. J Bone Miner Metab. 2013. PMID: 23076293 Clinical Trial.
-
The role of α-zearalanol in reversing bone loss induced by ovarian hormone deficiency in rats.J Bone Miner Metab. 2012 Mar;30(2):136-43. doi: 10.1007/s00774-011-0302-8. Epub 2011 Jul 20. J Bone Miner Metab. 2012. PMID: 21773701
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources